FORT WORTH, Texas, April 7, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that its Pharma Tech International Joint Venture, which sells wound care products within key international markets, has received new orders for the Company’s line of CellerateRX® powder and gel products. In Lebanon, the subsidiary just completed a $50,000 order for powder and gel with a second $100,000 order scheduled for shipment later this Month with expectations to ramp up to larger orders by 3rd quarter.
According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “I am very excited by these orders and the prospect for further growth in overseas sales. We believe that the international market represents a significant opportunity for our products due, in part, to the region’s high rate of diabetes and its associated complications.”
For additional news and information concerning the CellerateRx® line of wound care products, please visit Wound Management Technology’s newly relaunched product website www.CellerateRX.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved